Literature DB >> 12094378

Excessive survivin expression in thyroid lymphomas.

Masahiro Sugawara1, Fumio Matsuzuka, Shuji Fukata, Kanji Kuma, Farhad Moatamed, Bryan R Haugen.   

Abstract

Thyroid lymphoma occurs most commonly in the thyroid glands with a background of Hashimoto's thyroiditis. Therefore, it is occasionally difficult to distinguish lymphoma from Hashimoto's thyroiditis because of some cellular and histologic similarities. We have examined whether survivin or human telomerase reverse transcriptase (hTERT) expression can differentiate between the 2 disorders. Surgically removed tissue samples from 6 patients with thyroid lymphoma and 6 patients with Hashimoto's thyroiditis were analyzed for mRNA levels of survivin and hTERT by real-time quantitative reverse-transcription polymerase chain reaction. Expression of survivin protein was examined by immunohistochemical stain using a polyclonal antibody. Survivin mRNA levels were greater in thyroid lymphoma than in Hashimoto's thyroiditis: 49.1 +/-36.4 versus 6.6 +/-2.7 pg/ng rRNA (mean +/- SD) (P <0.005). Immunohistochemical stain confirmed an abundance of survivin protein in lymphoid cells of thyroid lymphoma. The amount of hTERT mRNA did not differ in the 2 disorders. Our study shows that measuring survivin mRNA levels or immunohistochemistry of the protein expression can be useful to aid the diagnosis of thyroid lymphoma when histologic diagnosis is difficult. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12094378     DOI: 10.1053/hupa.2002.124783

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

Review 2.  Thyroid lymphoma: recent advances in diagnosis and optimal management strategies.

Authors:  Siun Walsh; Aoife J Lowery; Denis Evoy; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-07-23

3.  Do Bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies?

Authors:  Amish M Gandhi; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

4.  Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin.

Authors:  Patrick Frost; Yijiang Shi; Bao Hoang; Joseph Gera; Alan Lichtenstein
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.